X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs CADILA HEALTHCARE - Comparison Results

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA CADILA HEALTHCARE PLETHICO PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x -1.1 24.0 - View Chart
P/BV x 0.0 6.0 0.3% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 PLETHICO PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
CADILA HEALTHCARE
Mar-17
PLETHICO PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs395460 85.8%   
Low Rs31305 10.3%   
Sales per share (Unadj.) Rs604.492.1 656.2%  
Earnings per share (Unadj.) Rs32.514.8 219.2%  
Cash flow per share (Unadj.) Rs51.318.5 277.7%  
Dividends per share (Unadj.) Rs03.20 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs473.668.0 696.5%  
Shares outstanding (eoy) m34.081,023.74 3.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.44.2 8.5%   
Avg P/E ratio x6.625.8 25.4%  
P/CF ratio (eoy) x4.220.7 20.1%  
Price / Book Value ratio x0.55.6 8.0%  
Dividend payout %021.6 0.0%   
Avg Mkt Cap Rs m7,262391,581 1.9%   
No. of employees `000NA16.9 0.0%   
Total wages/salary Rs m1,59615,002 10.6%   
Avg. sales/employee Rs ThNM5,594.5-  
Avg. wages/employee Rs ThNM890.1-  
Avg. net profit/employee Rs ThNM899.9-  
INCOME DATA
Net Sales Rs m20,59894,295 21.8%  
Other income Rs m3861,286 30.0%   
Total revenues Rs m20,98495,581 22.0%   
Gross profit Rs m2,81819,036 14.8%  
Depreciation Rs m6423,750 17.1%   
Interest Rs m1,593450 354.0%   
Profit before tax Rs m96916,122 6.0%   
Minority Interest Rs m0338 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3 0.0%   
Tax Rs m-1381,289 -10.7%   
Profit after tax Rs m1,10715,168 7.3%  
Gross profit margin %13.720.2 67.8%  
Effective tax rate %-14.38.0 -178.7%   
Net profit margin %5.416.1 33.4%  
BALANCE SHEET DATA
Current assets Rs m18,87760,223 31.3%   
Current liabilities Rs m11,89653,058 22.4%   
Net working cap to sales %33.97.6 446.0%  
Current ratio x1.61.1 139.8%  
Inventory Days Days3670 51.5%  
Debtors Days Days19888 224.4%  
Net fixed assets Rs m9,86172,984 13.5%   
Share capital Rs m3411,024 33.3%   
"Free" reserves Rs m12,33168,576 18.0%   
Net worth Rs m16,13969,600 23.2%   
Long term debt Rs m4,70624,684 19.1%   
Total assets Rs m33,146152,207 21.8%  
Interest coverage x1.636.8 4.4%   
Debt to equity ratio x0.30.4 82.2%  
Sales to assets ratio x0.60.6 100.3%   
Return on assets %8.110.3 79.4%  
Return on equity %6.921.8 31.5%  
Return on capital %12.317.9 68.5%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,40221,280 20.7%   
Fx outflow Rs m3,18410,874 29.3%   
Net fx Rs m1,21910,406 11.7%   
CASH FLOW
From Operations Rs m2,43713,495 18.1%  
From Investments Rs m-6,265-29,103 21.5%  
From Financial Activity Rs m2,49023,158 10.8%  
Net Cashflow Rs m-1,3377,556 -17.7%  

Share Holding

Indian Promoters % 82.7 74.8 110.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 8.3 51.8%  
FIIs % 5.5 5.9 93.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 11.0 68.2%  
Shareholders   10,665 44,069 24.2%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  SUN PHARMA  

Compare PLETHICO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 50.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 50.4% YoY). Sales on the other hand came in at Rs 33 bn (up 28.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS